Abstract
The human parvovirus B19 (PVB19), an erythrovirus causing diverse clinical manifestations ranging from asymptomatic or mild to more severe outcomes such as hydrops fetalis, is the only currently known human pathogenic parvovirus. Recently, PVB19 has been identified as a causative agent of pediatric and adult inflammatory cardiac diseases. The first hints for a possible etiopathogenetic role of the PVB19 infection and the development of cardiac dysfunction were demonstrated by molecular biology methods such as in situ hybridization (ISH) and polymerase chain reaction (PCR). In this regard, PVB19-associated inflammatory cardiomyopathy is characterized by infection of endothelial cells of small intracardiac arterioles and venules, which may be associated with endothelial dysfunction, impairment of myocardial microcirculation, and penetration of inflammatory cells in the myocardium.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Anderson MJ, Jones SE, Fisher-Hoch SP, Lewis E, Hall SM, Bartlett CL, Cohen BJ, Mortimer PP, Pereira MS (1983) Human parvovirus, the cause of erythema infectiosum (fifth disease)? Lancet 1:1378
Anderson MJ, Higgins PG, Davis LR, Willman JS, Jones SE, Kidd IM, Pattison JR, Tyrrell DA (1985) Experimental parvoviral infection in humans. J Infect Dis 152:257–265
Barah F, Vallely PJ, Chiswick ML, Cleator GM, Kerr JR (2001) Association of human parvovirus B19 infection with acute meningoencephalitis. Lancet 358:729–730
Berns KI (2001) Parvoviridae: the viruses and their replication. In: Fields BN, Knipe PM, Howley PM, et al (eds) Fields virology, 3rd edn. Lippincott-Raven, Philadelphia, pp 2173–2197
Brown KE, Anderson SM, Young NS (1993) Erythrocyte P antigen: cellular receptor for B19 parvovirus. Science 262:114–117
Brown KE, Hibbs JR, Gallinella G, Anderson SM, Lehman ED, McCarthy P, Young NS (1994a) Resistance to parvovirus B19 infection due to lack of virus receptor (erythrocyte P antigen). N Engl J Med 330:1192–1196
Brown KE, Young NS, Liu JM (1994b) Molecular, cellular and clinical aspects of parvovirus B19 infection. Crit Rev Oncol Hematol 16:1–31
Bultmann BD, Klingel K, Sotlar K, Bock CT, Baba HA, Sauter M, Kandolf R (2003a) Fatal parvovirus B19-associated myocarditis clinically mimicking ischemic heart disease: an endothelial cell-mediated disease. Hum Pathol 34:92–95
Bultmann BD, Klingel K, Sotlar K, Bock CT, Kandolf R (2003b) Parvovirus B19: a pathogen responsible formore than hematologic disorders. Virchows Arch 442:8–17
Corman LC, Dolson DJ (1992) Polyarteritis nodosa and parvovirus B19 infection. Lancet 339:491
Cossart YE, Field AM, Cant B, Widdows D (1975) Parvovirus-like particles in human sera. Lancet 1:72–73
Cotmore SF, McKie VC, Anderson LJ, Astell CR, Tattersall P (1986) Identification of the major structural and nonstructural proteins encoded by human parvovirus B19 and mapping of their genes by procaryotic expression of isolated genomic fragments. J Virol 60:548–557
Deiss V, Tratschin JD, Weitz M, Siegl G (1990) Cloning of the human parvovirus B19 genome and structural analysis of its palindromic termini. Virology 175:247–254
Dingli D, Pfizenmaier DH, Arromdee E, Wennberg P, Spittell PC, Chang-Miller A, Clarke BL (2000) Severe digital arterial occlusive disease and acute parvovirus B19 infection. Lancet 356:312–314
Doerig C, Beard P, Hirt B (1987) A transcriptional promoter of the human parvovirus B19 active in vitro and in vivo. Virology 157:539–542
Dorsch S, Liebisch G, Kaufmann B, Von LP, Hoffmann JH, Drobnik W, Modrow S (2002) The VP1 unique region of parvovirus B19 and its constituent phospholipase A2-like activity. J Virol 76:2014–2018
Drago F, Semino M, Rampini P, Rebora A (1999) Parvovirus B19 infection associated with acute hepatitis and a purpuric exanthem. Br J Dermatol 141:160–161
Enders G, Dotsch J, Bauer J, Nutzenadel W, Hengel H, Haffner D, Schalasta G, Searle K, Brown KE (1998) Life-threatening parvovirusB19-associated myocarditis and cardiac transplantation as possible therapy: two case reports. Clin Infect Dis 26:355–358
Finkel TH, Torok TJ, Ferguson PJ, Durigon EL, Zaki SR, Leung DY, Harbeck RJ, Gelfand EW, Saulsbury FT, Hollister JR (1994) Chronic parvovirus B19 infection and systemic necrotising vasculitis: opportunistic infection or aetiological agent? Lancet 343:1255–1258
Heegaard ED, Brown KE (2002) Human parvovirus B19. Clin Microbiol Rev 15:485–505
Hemauer A, von PA, Gigler A, Cassinotti P, Siegl G, Wolf H, Modrow S (1996) Sequence variability among different parvovirus B19 isolates. J Gen Virol 77:1781–1785
Hicks KE, Cubel RC, Cohen BJ, Clewley JP (1996) Sequence analysis of a parvovirus B19 isolate and baculovirus expression of the non-structural protein. Arch Virol 141:1319–1327
Hillingso JG, Jensen IP, Tom-Petersen L (1998) Parvovirus B19 and acute hepatitis in adults. Lancet 351:955–956
Hokynar K, Soderlund-Venermo M, Pesonen M, Ranki A, Kiviluoto O, Partio EK, Hedman K (2002) A new parvovirus genotype persistent in human skin. Virology 302:224–228
Hsu TC, Wu WJ, Chen MC, Tsay GJ (2004) Human parvovirus B19 nonstructural protein (NS1) induces apoptosis through mitochondria cell death pathway in COS-7 cells. Scand J Infect Dis 36:570–577
Kandolf R (2004) [Virus etiology of inflammatory cardiomyopathy]. Dtsch Med Wochenschr 129:2187–2192
Karetnyi YV, Beck PR, Markin RS, Langnas AN, Naides SJ (1999) Human parvovirus B19 infection in acute fulminant liver failure. Arch Virol 144:1713–1724
Kariyawasam HH, Gyi KM, Hodson ME, Cohen BJ (2000) Anaemia in lung transplant patient caused by parvovirus B19. Thorax 55:619–620
Klingel K, Sauter M, Bock CT, Szalay G, Schnorr JJ, Kandolf R (2004) Molecular pathology of inflammatory cardiomyopathy. Med Microbiol Immunol (Berl) 193:101–107
Koch WC (2001) Fifth (human parvovirus) and sixth (herpesvirus 6) diseases. Curr Opin Infect Dis 14:343–356
Kolmos HJ (1994) [Blood group P antigen is the cellular receptor for human parvovirus B 19]. Ugeskr Laeger 156:6227
Kuhl U, Pauschinger M, Bock T, Klingel K, Schwimmbeck CP, Seeberg B, Krautwurm L, Poller W, Schultheiss HP, Kandolf R (2003) Parvovirus B19 infection mimicking acute myocardial infarction. Circulation 108:945–950
Lehmann HW, Knoll A, Kuster RM, Modrow S (2003) Frequent infection with a viral pathogen, parvovirus B19, in rheumatic diseases of childhood. Arthritis Rheum 48:1631–1638
Liu JM, Green SW, Shimada T, Young NS (1992) Ablock in full-length transcript maturation in cells nonpermissive for B19 parvovirus. J Virol 66:4686–4692
Luo W, Astell CR (1993) A novel protein encoded by small RNAs of parvovirus B19. Virology 195:448–455
Malm C, Fridell E, Jansson K (1993) Heart failure after parvovirusB19 infection. Lancet 341:1408–1409
Mitchell LA (2002) Parvovirus B19 nonstructural (NS1) protein as a transactivator of interleukin-6 synthesis: common pathway in inflammatory sequelae of human parvovirus infections? J Med Virol 67:267–274
Moffatt S, Yaegashi N, Tada K, Tanaka N, Sugamura K (1998) Human parvovirus B19 nonstructural (NS1) protein induces apoptosis in erythroid lineage cells. J Virol 72:3018–3028
Moore TL (2000) Parvovirus-associated arthritis. Curr Opin Rheumatol 12:289–294
Mori J, Beattie P, Melton DW, Cohen BJ, Clewley JP (1987) Structure and mapping of the DNA of human parvovirus B19. J Gen Virol 68:2797–2806
Morinet F (1992) [Parvovirus B19 infection]. Pathol Biol (Paris) 40:621–622
Morinet F, Tratschin JD, Perol Y, Siegl G (1986) Comparison of 17 isolates of the human parvovirus B 19 by restriction enzyme analysis. Brief report. Arch Virol 90:165–172
Murry CE, Jerome KR, Reichenbach DD (2001) Fatal parvovirus myocarditis in a 5-year-old girl. Hum Pathol 32:342–345
Nguyen QT, Sifer C, Schneider V, Allaume X, Servant A, Bernaudin F, Auguste V, Garbarg-Chenon A (1999) Novel human erythrovirus associated with transient aplastic anemia. J Clin Microbiol 37:2483–2487
Nigro G, Bastianon V, Colloridi V, Ventriglia F, Gallo P, D’Amati G, Koch WC, Adler SP (2000) Human parvovirus B19 infection in infancy associated with acute and chronic lymphocytic myocarditis and high cytokine levels: report of 3 cases and review. Clin Infect Dis 31:65–69
Orth T, Herr W, Spahn T, Voigtlander T, Michel D, Mertens T, Mayet WJ, Dippold W, Meyer zum Buschenfelde KH (1997) Human parvovirus B19 infection associated with severe acute perimyocarditis in a 34-year-old man. Eur Heart J 18:524–525
Ozawa K, Ayub J, Young N (1988) Functionalmapping of the genome of the B19 (human) parvovirus by in vitro translation after negative hybrid selection. J Virol 62:2508–2511
Pamidi S, Friedman K, Kampalath B, Eshoa C, Hariharan S (2000) Human parvovirus B19 infection presenting as persistent anemia in renal transplant recipients. Transplantation 69:2666–2669
Pattison JR (1987) B19 virus-a pathogenic human parvovirus. Blood Rev 1:58–64
Pattison JR (1988) Diseases caused by the human parvovirus B19. Arch Dis Child 63:1426–1427
Salimans MM, van de Rijke FM, Raap AK, van Elsacker-Niele AM (1989) Detection of parvovirus B19 DNA in fetal tissues by in situ hybridization and polymerase chain reaction. J Clin Pathol 42:525–530
Schowengerdt KO, Ni J, Denfield SW, Gajarski RJ, Bowles NE, Rosenthal G, Kearney DL, Price JK, Rogers BB, Schauer GM, Chinnock RE, Towbin JA (1997) Association of parvovirus B19 genome in children with myocarditis and cardiac allograft rejection: diagnosis using the polymerase chain reaction. Circulation 96:3549–3554
Shade RO, Blundell MC, Cotmore SF, Tattersall P, Astell CR (1986) Nucleotide sequence and genome organization of human parvovirus B19 isolated from the serum of a child during aplastic crisis. J Virol 58:921–936
Sokal EM, Melchior M, Cornu C, Vandenbroucke AT, Buts JP, Cohen BJ, Burtonboy G (1998) Acute parvovirus B19 infection associated with fulminant hepatitis of favourable prognosis in young children. Lancet 352:1739–1741
Sol N, Morinet F, Alizon M, Hazan U (1993) Trans-activation of the long terminal repeat of human immunodeficiency virus type 1 by the parvovirus B19 NS1 gene product. J Gen Virol 74:2011–2014
Sol N, Le JJ, Vassias I, Freyssinier JM, Thomas A, Prigent AF, Rudkin BB, Fichelson S, Morinet F (1999) Possible interactions between the NS-1 protein and tumor necrosis factor alpha pathways in erythroid cell apoptosis induced by human parvovirus B19. J Virol 73:8762–8770
St Amand J, Astell CR (1993) Identification and characterization of a family of 11-kDa proteins encoded by the human parvovirus B19. Virology 192:121–131
Stahl HD, Seidl B, Hubner B, Altrichter S, Pfeiffer R, Pustowoit B, Liebert UG, Hofmann J, von Salis-Soglio G, Emmrich F (2000) High incidence of parvovirus B19 DNA in synovial tissue of patients with undifferentiated monoand oligoarthritis. Clin Rheumatol 19:281–286
Szekanecz Z, Humphries MJ, Ager A (1992) Lymphocyte adhesion to high endothelium is mediated by two beta 1 integrin receptors for fibronectin, alpha 4 beta 1 and alpha 5 beta 1. J Cell Sci 101:885–894
Takahashi Y, Murai C, Shibata S, Munakata Y, Ishii T, Ishii K, Saitoh T, Sawai T, Sugamura K, Sasaki T (1998) Human parvovirus B19 as a causative agent for rheumatoid arthritis. Proc Natl Acad Sci U S A 95:8227–8232
Trapani S, Ermini M, Falcini F (1999) Human parvovirus B19 infection: its relationship with systemic lupus erythematosus. Semin Arthritis Rheum 28:319–325
Tschöpe C, Bock CT, Kasner M, Noutsias M, Westermann D, Schwimmbeck PL, Pauschinger M, Poller WC, Kuhl U, Kandolf R, Schultheiss HP (2005) High prevalence of cardiac parvovirus B19 infection in patients with isolated left ventricular diastolic dysfunction. Circulation 111:879–886
Umene K, Nunoue T (1991) Genetic diversity of human parvovirus B19 determined using a set of restriction endonucleases recognizing four or five base pairs and partial nucleotide sequencing: use of sequence variability in virus classification. J Gen Virol 72:1997–2001
Urbich C, Dernbach E, Reissner A, Vasa M, Zeiher AM, Dimmeler S (2002) Shear stress-induced endothelial cell migration involves integrin signaling via the fibronectin receptor subunits alpha(5) and beta(1). Arterioscler Thromb Vasc Biol 22:69–75
Weigel-Kelley KA, Yoder MC, Srivastava A (2001) Recombinant human parvovirus B19 vectors: erythrocyte P antigen is necessary but not sufficient for successful transduction of human hematopoietic cells. J Virol 75:4110–4116
Weigel-Kelley KA, Yoder MC, Srivastava A (2003) Alpha5beta1 integrin as a cellular coreceptor for human parvovirus B19: requirement of functional activation of beta1 integrin for viral entry. Blood 102:3927–3933
Yoto Y, Kudoh T, Asanuma H, Numazaki K, Tsutsumi Y, Nakata S, Chiba S (1994) Transient disturbance of consciousness and hepatic dysfunction associated with human parvovirus B19 infection. Lancet 344:624–625
Yoto Y, Kudoh T, Haseyama K, Suzuki N, Chiba S (1996) Human parvovirus B19 infection associated with acute hepatitis. Lancet 347:868–869
Zhi N, Zadori Z, Brown KE, Tijssen P (2004) Construction and sequencing of an infectious clone of the human parvovirus B19. Virology 318:142–152
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2006 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Bock, C.T. (2006). Parvovirus B19: A New Emerging Pathogenic Agent of Inflammatory Cardiomyopathy. In: Schultheiss, H.P., Kapp, J.F., Grötzbach, G. (eds) Chronic Viral and Inflammatory Cardiomyopathy. Ernst Schering Research Foundation Workshop, vol 55. Springer, Berlin, Heidelberg . https://doi.org/10.1007/3-540-30822-9_6
Download citation
DOI: https://doi.org/10.1007/3-540-30822-9_6
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-23971-0
Online ISBN: 978-3-540-30822-5
eBook Packages: MedicineMedicine (R0)